77
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Intranasal administration of innovative triamcinolone acetonide encapsulated cubosomal in situ gel: formulation and characterization

, , , &
Pages 68-77 | Received 03 Aug 2023, Accepted 15 Dec 2023, Published online: 26 Dec 2023

References

  • Nag S, Manias JL, Stewart DJ. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol. 2009;118(2):197–217. doi: 10.1007/s00401-009-0541-0.
  • Raboel PH, Bartek J, Andresen M, et al. Intracranial pressure monitoring: invasive versus non-invasive methods—a review. Crit Care Res Pract. 2012;2012:950393–950314. doi: 10.1155/2012/950393.
  • Unterberg AW, Stover J, Kress B, et al. Edema and brain trauma. Neuroscience. 2004;129(4):1021–1029. doi: 10.1016/j.neuroscience.2004.06.046.
  • Kuramatsu JB, Huttner HB, Schwab S. Advances in the management of intracerebral hemorrhage. J Neural Transm (Vienna). 2013;120(Suppl 1):S35–S41. doi: 10.1007/s00702-013-1040-y.
  • Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab. 2016;36(3):513–538. doi: 10.1177/0271678X15617172.
  • Rabinstein AA. Treatment of cerebral edema. Neurologist. 2006;12(2):59–73. doi: 10.1097/01.nrl.0000186810.62736.f0.
  • Raslan A, Bhardwaj A. Medical management of cerebral edema. Neurosurg Focus. 2007;22(5):E12–12. doi: 10.3171/foc.2007.22.5.13.
  • Walcott BP, Kahle KT, Simard JM. Novel treatment targets for cerebral edema. Neurotherapeutics. 2012;9(1):65–72. doi: 10.1007/s13311-011-0087-4.
  • Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. Int J Mol Sci. 2015;16(5):9949–9975. doi: 10.3390/ijms16059949.
  • Triamcinolone acetonide cream (triamcinolone acetonide) dose, indications, adverse effects, interactions… from PDR.net. 2023
  • Jha SK. Cerebral edema and its management. Med J Armed Forces India. 2003;59(4):326–331. doi: 10.1016/S0377-1237(03)80147-8.
  • Bourganis V, Kammona O, Alexopoulos A, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337–362. doi: 10.1016/j.ejpb.2018.05.009.
  • Alsarra IA, Hamed AY, Alanazi FK, et al. Vesicular systems for intranasal drug delivery. Drug Deliv Central Nervous Syst. 2010;45:175–203. doi: 10.1007/978-1-60761-529-3_8.
  • Patil RP, Pawara DD, Gudewar CS, et al. Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil HCl to brain. J Liposome Res. 2019;29(3):264–273. doi: 10.1080/08982104.2018.1552703.
  • Dhadwal A, Sharma DR, Pandit V, et al. Cubosomes: a novel carrier for transdermal drug delivery. J Drug Delivery Ther. 2020;10(1):123–130. doi: 10.22270/jddt.v10i1.3814.
  • Salah S, Mahmoud AA, Kamel AO. Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. Drug Deliv. 2017;24(1):846–856. doi: 10.1080/10717544.2017.1326539.
  • Ferreira SC, Bruns RE, Ferreira HS, et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597(2):179–186. doi: 10.1016/j.aca.2007.07.011.
  • Fernandes AV, Pydi CR, Verma R, et al. Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers. Braz J Pharm Sci. 2020;16:56. doi: 10.1590/s2175-97902019000318069.
  • Avachat AM, Parpani SS. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerf. 2015;126:87–97. doi: 10.1016/j.colsurfb.2014.12.014.
  • Hakeem EA, El-Mahrouk GM, Abdelbary G, et al. Freeze-dried clopidogrel loaded lyotropic liquid crystal: Box-Behnken optimization, in-vitro and in-vivo evaluation. Curr Drug Deliv. 2020;17(3):207–217. doi: 10.2174/1567201817666200122161433.
  • Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv. 2014;21(1):62–73. doi: 10.3109/10717544.2013.849778.
  • Nasr M, Ghorab MK, Abdelazem A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta Pharm Sin B. 2015;5(1):79–88. doi: 10.1016/j.apsb.2014.12.001.
  • Schmolka IR. Artificial skin I. Preparation and properties of pluronic F‐127 gels for treatment of burns. J Biomed Mater Res. 1972;6(6):571–582. doi: 10.1002/jbm.820060609.
  • Ahirrao M, Shrotriya S. In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting. Drug Dev Ind Pharm. 2017;43(10):1686–1693. doi: 10.1080/03639045.2017.1338721.
  • Gupta SK, Kumar S. An overview on intranasal drug delivery system: recent technique and its contribution in therapeutic management. Curr Res Pharmaceut Sci. 2019; 9(2):17–23. doi: 10.24092/crps.2019.090201.
  • Kempwade A, Taranalli A. Formulation and evaluation of thermoreversible, mucoadhesive in situ intranasal gel of rizatriptan benzoate. J Sol-Gel Sci Technol. 2014;72(1):43–48. doi: 10.1007/s10971-014-3422-5.
  • Pund S, Rasve G, Borade G. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur J Pharm Sci. 2013;48(1–2):195–201. doi: 10.1016/j.ejps.2012.10.029.
  • Verekar RR, Gurav SS, Bolmal U. Thermosensitive mucoadhesive in situ gel for intranasal delivery of almotriptan malate: formulation, characterization, and evaluation. J Drug Delivery Sci Technol. 2020; 58:101778. doi: 10.1016/j.jddst.2020.101778.
  • Nour SA, Abdelmalak NS, Naguib MJ, et al. Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: in vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies. Drug Deliv. 2016;23(9):3681–3695. doi: 10.1080/10717544.2016.1223216.
  • Kancharla S, Zoyhofski NA, Bufalini L, et al. Association between nonionic amphiphilic polymer and ionic surfactant in aqueous solutions: effect of polymer hydrophobicity and micellization. Polymers (Basel). 2020;12(8):1831. doi: 10.3390/POLYM12081831.
  • Kamel AO, Awad GA, Geneidi AS, et al. Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AapsPharmscitech. 2009;10(4):1427–1436. doi: 10.1208/s12249-009-9342-y.
  • Sayed S, Abdel-Moteleb M, Amin MM, et al. Cubogel as potential platform for glaucoma management. Drug Deliv. 2021;28(1):293–305. doi: 10.1080/10717544.2021. 1872740
  • Elfaky MA, Sirwi A, Tolba HH, et al. Development, optimization, and antifungal assessment of ocular gel loaded with ketoconazole cubic liquid crystalline nanoparticles. J Pharm Sci. 2021;110(5):2210–2220. doi: 10.1016/j.xphs.2021.02.022.
  • Pal SL, Jana U, Manna PK, et al. Nanoparticle: an overview of preparation and characterization. J Appl Pharmaceut Sci. 2011;30:228–234.
  • Abou Youssef NA, Kassem AA, Farid RM, et al. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm. 2018;548(1):609–624. doi: 10.1016/j.ijpharm.2018.07.014.
  • Okur NÜ, Yozgatli V, Okur ME. In vitro–in vivo evaluation of tetrahydrozoline‐loaded ocular in situ gels on rabbits for allergic conjunctivitis management. Drug Dev Res. 2020; 81(6):716–727. doi: 10.1002/ddr.21677.
  • Ghazwani M, Vasudevan R, Kandasamy G, et al. Formulation of intranasal mucoadhesive thermotriggered in situ gel containing mirtazapine as an antidepressant drug. Gels. 2023;9(6):457. doi: 10.3390/gels9060457.
  • Mallappa DP, Chelsea FR, Ratnakar RP, et al. Development and characterization of mucoadhesive buccal gel containing lipid nanoparticles of triamcinolone acetonide. IJPER. 2020;54(3s):S505–s511. doi: 10.5530/ijper.54.3s.149.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.